VTE Risk Assessment Audit

Free projects are complete and ready to use. Paid projects can also be adapted to your local requirements. This project uses a fixed Lazomis clinical configuration of 20 audit criteria across eligibility and VTE risk assessment, bleeding risk and contraindications, pharmacological and mechanical prophylaxis decisions, reassessment and ongoing review, discharge and transfer communication, and documentation quality. Data collection, dashboards, findings, improvement planning, re-audit and every output are included at no cost.

• Doctors, nurses, pharmacists and ACPs/PAs
• Admission, ward, surgical, trauma and critical care teams
• Thrombosis, anticoagulation and medicines optimisation teams
• QI leads, governance and patient safety teams

• Measure completion and timeliness of VTE and bleeding risk assessment
• Assess documentation of pharmacological and mechanical prophylaxis decisions
• Review reassessment, ongoing and discharge prophylaxis planning
• Identify variation by clinical area, care setting and assessment context
• Generate governance-ready and ARCP-ready evidence

• Anonymised case identifier
• Age band, recorded sex/gender, care setting, assessment context and mobility/risk context
• Clinical area / location
• 20 fixed VTE risk assessment criteria (Yes / No / Not applicable)
• Free-text learning points

• Live dashboard
• Audit report (Word)
• Executive summary (Word)
• Excel workbook
• PowerPoint presentation
• Conference poster
• ARCP evidence summary

• Designed to use anonymised or pseudonymised audit identifiers.
• This tool supports, but does not replace, clinical judgement.
• Local policy, formulary and specialist advice should be followed.
• Organisations remain responsible for local governance arrangements.
• This audit tool supports documentation review and quality improvement. It does not replace clinical judgement, local VTE policy, anticoagulation guidance, prescribing guidance, specialist advice or emergency escalation pathways.
• Audit data alone cannot support conclusions about preventability, negligence, inappropriate prescribing, avoidable harm, hospital-acquired thrombosis causality or breach of policy.
• Assessment timeframes, risk categories, prophylaxis choice, dose and duration are set by local policy and are not defined by this tool.
• Use anonymous case identifiers only — never patient-identifiable information.

Supporting guidance from the Lazomis QI Resource Library. Authoritative clinical standards referenced by this project remain separate.

• Patient FlowOptimising Patient Flow Between Emergency Department and Acute Medical UnitThis guide explores common challenges in patient flow between the Emergency Department (ED) and Acute Medical Units (AMU), offering practical strategies for improvement, focusing on clinical and operational alignment.
• Clinical GovernanceClinical Governance Explained: A Framework for Quality and Safety in the NHSThis article defines clinical governance, outlines its key pillars, and explains why a robust framework is crucial for maintaining and improving patient safety and quality of care within the NHS.
• Patient SafetyDiagnostic Delay: Understanding and Mitigating a Critical Patient Safety RiskDiagnostic delay is a significant patient safety concern across all healthcare settings. This guide explains why timely diagnosis is crucial, details the common factors contributing to delays, and provides actionable strategies for healthcare professionals and teams to mitigate these risks.
• Patient SafetyImplementing Effective Safety Huddles in Clinical PracticeThis resource provides practical guidance on establishing and participating in effective safety huddles to proactively identify and mitigate patient safety risks within clinical teams.